CeMBR - New Jersey Center for Biomaterials

More documents

Recommendations

Info

Wound healing and regeneration productsdeveloped by MBI team members• Hollinger: BioMimetics Therapeutics’ growth-factor enhanced matrix forperiodontal bone defects– the first FDA-cleared recombinant growth factor containing product forthe periodontal market• Kohn: TyRx Pharma’s hernia repair devices– combinatorially designed, resorbable polymer• Kohn: Reva/Boston Scientific’s degradable vascular stent– combinatorially designed radioopaque polymer composition• Ducheyne: Orthovita’s bone regeneration– FDA-cleared porous nanoparticle tricalcium phosphates• Ducheyne/Devore: Gentis’ spinal disc repair– injectable emulsion polymer entering human trials• Langer: 500 patents licensed to 187 companies and 22 start-ups areimpacting medical practice in drug delivery and tissue regeneration08 November 2006 CeMBR 2nd Military Biomaterials Roadmap Workshop
Preliminary Workshop Breakout Topics• Consider the current roadmap: what would make the roadmap more valuableto the military, industry and academia? How do we go about improving it to achievethat? (e.g., is an in depth market study needed of segment values)? How can wedevelop clear product specifications in each roadmap area (wound care, tissueregeneration, soldier protection, sensors & diagnostics)? What kind of organization isneeded to succeed in meeting the technology and business challenges? How do webuild industry participation? How do we fund the R&D needed?• Consider regeneration of tissue damaged by major combat wounds:what are the major technical challenges and the strengths & weakness of currentresearch paradigms? What radical new concepts can we propose for tissueregeneration that would go beyond the current research thrusts? What kind oforganization is needed to succeed in meeting the technology and businesschallenges?• Consider soldier protection from chemical and biological agents, oreven from bullets, shrapnel, fire and explosions: what are the majortechnical challenges and the strengths & weakness of current research paradigms?What radical new concepts can we propose for proactive, bioactive biomaterials forprotection rather than for post-exposure therapeutic treatments that would go beyondcurrent thinking and current research thrusts? What kind of organization is needed tomeet the technology and business challenges?08 November 2006 CeMBR 2nd Military Biomaterials Roadmap Workshop
Page 1 and 2: The Military Biomaterials Roadmap:G
Page 3 and 4: 1 st Military Biomaterials Roadmap
Page 5 and 6: 1 st Military Biomaterials Roadmap
Page 7 and 8: CeMBR’s Mission• The Center for
Page 9 and 10: Current CeMBR projects address all
Page 11 and 12: MBI’s Approach to Limb Regenerati
Page 13 and 14: Conclusions• The Military Biomate
Page 15 and 16: BioCure set GelSpray TM product spe
Page 17: MBI focused on translational R&DCel

CeMBR - New Jersey Center for Biomaterials

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?